50-52-2.msds-cas.com

Name :Thioridazine
Cas No. :50-52-2
Synonyms:THIORIDAZINE;10-((1-methyl-2-piperidyl)ethyl)-2-(met
hylthio)-phenothiazin;10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(meth
ylthio)-10h-phenothiazin;10-(2-(1-methyl-2-piperidyl)ethyl)-2-(met
hylthio)-phenothiazin;10-(2-(1-Methyl-2-piperidyl)ethyl)-2-(methyl
thio)phenothiazine;10-[2-(1-Methyl-2-piperdiyl)ethyl]-2-(methylthi
o)phenothiazine;10-[2-(1-Methyl-2-piperidinyl)ethyl]-2-(methylsulf
anyl)-10H-phenothiazine;10H-Phenothiazine,
10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-
Molecular Formula:C21H26N2S2
Molecular Weight:370.57
Wiki:
Not to be confused with Thorazine. Thioridazine Systematic (IUPAC)
name 10-{2-[(RS)-1-Methylpiperidin-2-yl]ethyl}-
2-methylsulfanylphenothiazine Clinical data AHFS/Drugs.com
Consumer Drug Information MedlinePlus a682119 Licence data
US Daily Med:link Pregnancy cat. C (AU) C (US) Legal status
Prescription Only (S4) (AU) â„ž-only (US) Withdrawn by the
manufacturer in the UK, Canada and Australia Routes Oral
Pharmacokinetic data Bioavailability incomplete Metabolism hepatic
(at least partly mediated by CYP2D6) Half-life 21-24 hours[1]
Excretion faeces Identifiers CAS number 50-52-2Â Y ATC code N05
AC02 PubChem CID 5452 IUPHAR ligand 100 DrugBank DB00679
ChemSpider 5253Â Y UNII N3D6TG58NIÂ Y KEGG D00373Â Y
ChEBI CHEBI:9566Â Y ChEMBL CHEMBL479Â Y Chemical data
Formula C21H26N2S2Â Mol. mass 370.577 SMILES
S(c2cc1N(c3c(Sc1cc2)cccc3)CCC4N(C)CCCC4)C InChI
InChI=1S/C21H26N2S2/c1-22-13-6-5-7-16(22)12-14-23-18-8-3-4-9-2
0(18)25-21-11-10-17(24-2)15-19(21)23/h3-4,8-11,15-16H,5-7,12-14H
2,1-2H3Â Y
Key:KLBQZWRITKRQQV-UHFFFAOYSA-NÂ Y Â YÂ (what is
this?)Â Â (verify) Thioridazine (Mellaril (DE, BD, ET, ID, BR),
Melleril (withdrawn worldwide in 2005[2]), Sonapax (RU), Thioril (IN)
) is a piperidine typical antipsychotic drug belonging to the
phenothiazine drug group and was previously widely used in the
treatment of schizophrenia and psychosis. Due to concerns about
cardiotoxicity and retinopathy at high doses this drug has been
withdrawn in many countries (including the UK and Australia) and in
other countries it is not commonly prescribed, reserved for patients
who have failed to respond to, or have contraindications for, more
widely used antipsychotics. In older references, it is sometimes
described as atypical,[3] but more recently it is usually described as
typical,[4] with the term "atypical" usually reserved for agents showing
D4 selectivity or serotonin antagonism. Its perceived atypical effects
(namely its comparatively low propensity for extrapyramidal side
effects) are likely the result of its potent anticholinergic effects. Get
.

Source: http://50-52-2.msds-cas.com/msds-cas.pdf